Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer

After chemotherapy for metastatic, nonseminomatous testicular cancer, small, retroperitoneal lymph nodes still harbor mature teratoma or viable cancer cells in less than half of patients with normal tumor markers. Surgical resection is an effective treatment to remove residual masses, but observation may also be considered.

[1]  J P Donohue,et al.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Tait,et al.  Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. , 1984, British Journal of Cancer.

[3]  H. Brachinger,et al.  Decision analysis , 1997 .

[4]  A. Horwich,et al.  The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Boetes,et al.  The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. , 1990, British journal of urology.

[6]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[7]  J. Habbema,et al.  Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Ulbright,et al.  Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Habbema,et al.  Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. , 1994, European journal of cancer.

[10]  E. Steyerberg,et al.  Postchemotherapy surgery in nonseminoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Baldetorp,et al.  Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Horwich,et al.  Ejaculatory dysfunction after retroperitoneal lymphadenectomy. , 1993, European urology.

[13]  L. Einhorn,et al.  Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction , 1981, Cancer.

[14]  D. Dearnaley,et al.  Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. , 1993, British journal of urology.

[15]  R. Ravi Growing teratoma syndrome. , 1995, Urologia internationalis.

[16]  O. Nativ,et al.  The malignant potential of postchemotherapy residual mature teratoma for disseminated nonseminomatous testicular tumors. , 1994, European urology.

[17]  L. Einhorn Treatment of testicular cancer: a new and improved model. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Habbema,et al.  Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. , 1996, British Journal of Cancer.

[19]  L. Einhorn,et al.  Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Cornelisse,et al.  Karyotyping and DNA flow cytometry of mature residual teratoma after intensive chemotherapy of disseminated nonseminomatous germ cell tumor of the testis: a report of two cases. , 1986, Cancer genetics and cytogenetics.

[21]  D. Sleijfer,et al.  Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin‐vinblastine‐bleomycin chemotherapy , 1988, Journal of surgical oncology.

[22]  N. Geller,et al.  Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Fasoli [Clinical decision analysis]. , 1986, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

[24]  J. Habbema,et al.  Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. , 1993, British Journal of Cancer.

[25]  K. Sikora Testicular Cancer-Investigation and Management , 1993, British Journal of Cancer.

[26]  W. Hendry Decision making in abdominal surgery following chemotherapy for testicular cancer. , 1995, European journal of cancer.

[27]  W. Molenaar,et al.  Complications of the post-chemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. , 1997, British journal of urology.

[28]  R. Motzer,et al.  Testicular germ-cell cancer. , 1997, The New England journal of medicine.

[29]  S. Fosså,et al.  Psychosocial well-being in testicular cancer patients. , 1991, European Journal of Cancer.

[30]  S. Fosså,et al.  Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Kopecky,et al.  Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. , 1987, The Journal of urology.